Clark Estates Inc’s Myriad Genetics MYGN Stock Holding History

Clark Estates Inc’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-25,000	Closed	-$646K	–	92
2017 Q2	$646K	Sell	25,000 -90,000	-78%	-$1.91M	0.11%	86
2017 Q1	$2.21M	Hold	115,000	–	–	0.34%	73
2016 Q4	$1.92M	Hold	115,000	–	–	0.32%	79
2016 Q3	$2.37M	Buy	+115,000	New	+$2.92M	0.46%	77
2015 Q1	–	Sell	-67,000	Closed	-$2.28M	–	120
2014 Q4	$2.28M	Sell	67,000 -28,000	-29%	-$994K	0.34%	83
2014 Q3	$3.66M	Hold	95,000	–	–	0.58%	27
2014 Q2	$3.7M	Hold	95,000	–	–	0.53%	31
2014 Q1	$3.25M	Hold	95,000	–	–	0.49%	29
2013 Q4	$1.99M	Buy	+95,000	New	+$2.4M	0.28%	75
2013 Q3	–	Sell	-43,000	Closed	-$1.16M	–	133
2013 Q2	$1.16M	Buy	+43,000	New	+$1.25M	0.2%	91

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Clark Estates Inc's MYGN Position: Q3 2017 in Review

Clark Estates Inc sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 25,000 shares — an estimated $646K sold.

Clark Estates Inc first reported a position in MYGN in Q2 2013 and held it in 10 quarters. The position peaked at $3.7M in Q2 2014. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

Clark Estates Inc reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
Clark Estates Inc sold 25,000 Myriad Genetics shares in Q3 2017, an estimated $646K.
Clark Estates Inc first reported a position in Myriad Genetics in Q2 2013 and held it in 10 quarters.
Clark Estates Inc's Myriad Genetics position peaked at $3.7M in Q2 2014.
220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on Clark Estates Inc's 13F filing for Q3 2017, filed 16 Oct 2017.